Regression of glioma in rat models by intranasal application of parvovirus H-1

Clinical Cancer Research

Volumn 17, Issue 16, 2011, Pages 5333-5342

  Kiprianova, Irina ^a   Thomas, Nadja ^a   Ayache, Ali ^a   Fischer, Manuel ^a   Leuchs, Barbara ^a   Klein, Michèle ^a,b   Rommelaere, Jean ^a,b   Schlehofer, Jörg R ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Cancer Virotherapy Unit   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC PARVOVIRUS; ONCOLYTIC PARVOVIRUS H-1; REGULATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TISSUE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GLIOMA; H-1 PARVOVIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; RAT; STEREOTACTIC PROCEDURE; TUMOR REGRESSION; VIRION; VIRUS REPLICATION; WISTAR RAT; XENOGRAFT;

ADMINISTRATION, INTRANASAL; ANIMALS; BRAIN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA, VIRAL; FEMALE; GLIOMA; H-1 PARVOVIRUS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; ONCOLYTIC VIROTHERAPY; PARVOVIRIDAE INFECTIONS; POLYMERASE CHAIN REACTION; RATS; RATS, WISTAR; TREATMENT OUTCOME; TUMOR BURDEN; VIRAL PROTEINS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051677478     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3124     Document Type: Article

References (30)

1. Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey WH 2nd, et al. New therapeutic approach for brain tumors: intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol 2008;10:112-120
2. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 2004;100:472-479 (Pubitemid 38269075)
3. Mamot C, Nguyen JB, Pourdehnad M, Hadaczek P, Saito R, Bringas JR, et al. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol 2004;68:1-9. (Pubitemid 39137344)
4. Saito R, Krauze MT, Noble CO, Tamas M, Drummond DC, Kirpotin DB, et al. Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery. J Neurosci Methods 2006;154:225-232 (Pubitemid 43949058)
5. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 1994;91:2076-2080 (Pubitemid 24092045)
6. Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol 2000;2:45-59.
7. Thorne RG, Emory CR, Ala TA, Frey WH 2nd. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res 1995;692:278-282
8. Thorne RG, Frey WH 2nd. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 2001;40:907-946 (Pubitemid 34066688)
9. Romeo VD, deMeireles J, Sileno AP, Pimplaskar HK, Behl CR. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Deliv Rev 1998;29:89-116. (Pubitemid 28044088)
10. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127:481-496 (Pubitemid 38950662)
11. Hanson LR, Frey WH 2nd. Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. J Neuroimmune Pharmacol 2007;2:81-86
12. Wang F, Jiang X, Lu W. Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats. Int J Pharm 2003;263:1-7. (Pubitemid 37087927)
13. Sakane T, Yamashita S, Yata N, Sezaki H. Transnasal delivery of 5-fluorouracil to the brain in the rat. J Drug Target 1999;7:233-240 (Pubitemid 30028967)
14. Wang D, Gao Y, Yun L. Study on brain targeting of raltitrexed following intranasal administration in rats. Cancer Chemother Pharmacol 2006;57:97-104. (Pubitemid 41704922)
15. Ozduman K, Wollmann G, Piepmeier JM, van den Pol AN. Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J Neurosci 2008;28:1882-1893 (Pubitemid 351302677)
16. Rommelaere J, Geletneky K, Angelova AL, Daeffler L, Dinsart C, Kiprianova I, et al. Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev 2010;21:185-196
17. Geletneky K, Kiprianova I, Ayache A, Koch R, Herrero y Calle M, Deleu L, et al. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models. Neuro Oncol 2010;12:804-814
18. Tattersall P. The evolution of parvoviral taxonomy. In: Kerr JR, Cotmore SF, Bloom ME, Linden RM, Parrish CR, editors. The parvoviruses. London: Hodder Arnold; 2006. p. 5-14.
19. Cornelis JJ, Deleu L, Koch U, Rommelaere J. Parvovirus oncosuppression. In: Kerr JR, Cotmore SF, Bloom ME, Linden RM, Parrish CR, editors. The parvoviruses. London: Hodder Arnold; 2006.
20. Di Piazza M, Mader C, Geletneky K, Herrero YCM, Weber E, Schlehofer J, et al. Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J Virol 2007;81:4186-4198 (Pubitemid 46586913)
21. Cotmore SF, Tattersall P. Parvoviral host range and cell entry mechanisms. Adv Virus Res 2007;70:189-232.
22. Rommelaere J, Giese N, Cziepluch C, Cornelis JJ. Parvoviruses as anti-cancer agents. In: Sinkovics JG, Horvath JC, editors. Viral therapy of human cancers. New York: Marcel Dekker; 2005. p. 627-675
23. Wrzesinski C, Tesfay L, Salome N, Jauniaux JC, Rommelaere J, Cornelis J, et al. Chimeric and pseudotyped parvoviruses minimize the contamination of recombinant stocks with replication-competent viruses and identify a DNA sequence that restricts parvovirus H-1 in mouse cells. J Virol 2003;77:3851-3858 (Pubitemid 36297305)
24. Paradiso PR. Analysis of the protein-protein interactions in the parvovirus H-1 capsid. J Virol 1983;46:94-102. (Pubitemid 13161247)
25. Rayet B, Lopez-Guerrero JA, Rommelaere J, Dinsart C. Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway. J Virol 1998;72:8893-8903 (Pubitemid 28471833)
26. Schlehofer JR, Gissmann L, Matz B, zur Hausen H. Herpes simplex virus-induced amplification of SV40 sequences in transformed Chinese hamster embryo cells. Int J Cancer 1983;32:99-103. (Pubitemid 13032543)
27. Kestler J, Neeb B, Struyf S, Van Damme J, Cotmore SF, D'Abramo A, et al. cis requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses. Hum Gene Ther 1999;10:1619-1632 (Pubitemid 29328206)
28. Gart JJ, Krewski D, Lee PN, Tarone RE, Wahrendorf J. The design and analysis of long-term animal experiments. In: IACR, editor. Statistical methods in cancer research. Lyon: IARC; 1986.
29. Zee YC, MacLachlan NJ. Parvovridae and circoviridae. In: Hirsh DC, MacLachlan NJ, Walker RL, editors. Veterinary microbiology. 2nd ed. Blackwell Publishing; 2004. p. 301-11.
30. Parrish CA. Autonomous parvoviruses variation and evolution. In: J R Kerr SFC, M E Bloom, R M Linden, C R Parrish, editors. Parvoviruses. New York: Oxford University Press Inc; 2006. p. 47.